These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30688385)

  • 1. Prospective evaluation of pretreatment and intratreatment FDG PET-CT SUV stability in primary head and neck cancer.
    Mendez LC; Conrad T; Lee J; Smith B; Brotherston D; Le T; Kiss A; Caldwell CB; Karam I; Poon I
    Head Neck; 2019 Jun; 41(6):1889-1894. PubMed ID: 30688385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change.
    Hoang JK; Das SK; Choudhury KR; Yoo DS; Brizel DM
    AJNR Am J Neuroradiol; 2013 Jul; 34(7):1428-33. PubMed ID: 23391836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study.
    Schinagl DA; Span PN; Oyen WJ; Kaanders JH
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1449-58. PubMed ID: 21461734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer.
    Moule RN; Kayani I; Prior T; Lemon C; Goodchild K; Sanghera B; Wong WL; Saunders MI
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):364-71. PubMed ID: 21109410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to pretreatment and intratreatment imaging of head and neck squamous cell carcinoma patients undergoing (chemo) radiotherapy in a research setting.
    Martens RM; Koopman T; Noij DP; de Bree R; Vergeer MR; Zwezerijnen G; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
    Clin Imaging; 2021 Jan; 69():82-90. PubMed ID: 32693228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer.
    Machtay M; Natwa M; Andrel J; Hyslop T; Anne PR; Lavarino J; Intenzo CM; Keane W
    Head Neck; 2009 Feb; 31(2):195-201. PubMed ID: 19107945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M
    Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of
    van den Bosch S; Dijkema T; Philippens MEP; Terhaard CHJ; Hoebers FJP; Kaanders JHAM; Oyen WJG
    Radiother Oncol; 2019 Jan; 130():39-45. PubMed ID: 30005954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.
    Imsande HM; Davison JM; Truong MT; Devaiah AK; Mercier GA; Ozonoff AJ; Subramaniam RM
    AJR Am J Roentgenol; 2011 Oct; 197(4):976-80. PubMed ID: 21940588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
    Schouten CS; Hakim S; Boellaard R; Bloemena E; Doornaert PA; Witte BI; Braakhuis BJ; Brakenhoff RH; Leemans CR; Hoekstra OS; de Bree R
    Head Neck; 2016 Apr; 38(4):529-35. PubMed ID: 25352335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
    Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
    Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.